Kinea Bio raised $1.1 million to advance next-generation AAV-based gene therapies for neuromuscular diseases, leveraging engineered tissue modeling and splicing strategies to treat rare genetic disorders.
Kinea Bio raised $1.1 million to advance next-generation AAV-based gene therapies for neuromuscular diseases, leveraging engineered tissue modeling and splicing strategies to treat rare genetic disorders.
